Skip to main content
Clinical Trials/NCT06421090
NCT06421090
Recruiting
Not Applicable

Safety and Feasibility of Transauricular Vagus Nerve Stimulation in Improving Postoperative Delirium in Elderly Patients: a Randomized Controlled Study

Beijing Tiantan Hospital1 site in 1 country150 target enrollmentMay 21, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vagus Nerve Stimulation
Sponsor
Beijing Tiantan Hospital
Enrollment
150
Locations
1
Primary Endpoint
TaVNS tolerance
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

To investigate the efficacy and safety of perioperative Transauricular vagal nerve stimulation in improving Postoperative Delirium in elderly patients undergoing elective surgery Lay the groundwork for a Phase III study.

Detailed Description

This study aims to conduct a prospective, randomized controlled clinical trial on the preventive use of Transauricular vagal nerve stimulation(taVNS) to improve the incidence of Postoperative Delirium(POD) in elderly patients undergoing anesthesia surgery. The intervention group will receive taVNS, while the control group will only wear a taVNS stimulator without current stimulation.

Registry
clinicaltrials.gov
Start Date
May 21, 2024
End Date
December 31, 2025
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Beijing Tiantan Hospital
Responsible Party
Principal Investigator
Principal Investigator

Ruquan Han

professor

Beijing Tiantan Hospital

Eligibility Criteria

Inclusion Criteria

  • Age≥65 years
  • Expected operation time≥ 2 hours
  • Postoperative hospital stay≥ 4 days
  • Sign the informed consent form

Exclusion Criteria

  • Neurosurgery or cardiac surgery
  • Emergency surgery within 6 hours of admission
  • End-stage disease with an expected survival of \< 3 months
  • Preoperative severe cognitive dysfunction affected perioperative cognitive function assessment
  • Severe sinus bradycardia, AVB of degree II and above, pacemaker placement

Outcomes

Primary Outcomes

TaVNS tolerance

Time Frame: 1-5 days after surgery

The proportion of subjects who completed all the expected interventions

Incidence of adverse events

Time Frame: At discharge,an average of 2 weeks

Myocardial infarction, cardiac arrest, pulmonary embolism, infection, etc

Secondary Outcomes

  • Postoperative pain(1-5 days after surgery)
  • Incidence of POD at discharge or within 5 days postoperatively(At discharge or within 5 days postoperatively)
  • All-cause mortality(on the 90 days)
  • Incidence of cognitive decline(Day 1 before surgery, day 5 after surgery, day 90 after surgery)
  • Time of anesthesia recovery(Within 2 hours after the end of the surgery)

Study Sites (1)

Loading locations...

Similar Trials